Radiopharmaceuticals 1994. Nil desperandum. European Association of Nuclear Medicine Committees on Radiopharmaceuticals and Positron Emission Tomography.
On the basis of the discussions at a symposium held in Düsseldorf and attended by representatives of various interested bodies, European legislation as it affects radiopharmaceuticals is reviewed. Due consideration is given to the new, centralised and decentralised, registration procedures, effective since 1 January 1995. The dossier required to support an application for marketing authorisation is discussed, separate consideration being given to single-photon emitters, therapeutic radio-nuclides and positron-emitting radiopharmaceuticals. The role of the European Pharmacopoiea is also considered. It is concluded that the new, modified procedures for the registration of medicinal products in the European Union may actually inhibit free availability of radio-pharmaceuticals within the Community, and that there is a strong case for modification of the European Directives so that radiopharmaceuticals are placed in a separate category to therapeutic drugs, with less stringent registration requirements.
Cox
P H
PH
Dr. Daniel den Hoed Cancer Center, Department of Nuclear Medicine, Rotterdam, The Netherlands.
Meyer
G J
GJ
D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D017850:Economics, Pharmaceutical; D005060:Europe; D005062:European Union; D006801:Humans; D007885:Legislation, Pharmacy; D009683:Nuclear Medicine / Q000331:legislation & jurisprudence*; D010602:Pharmacopoeias as Topic; D011868:Radioisotopes / Q000600:supply & distribution*
D011868:Radioisotopes